PHASE 2B TRIAL TO EVALUATE THE SAFETY AND FACTOR IX LEVELS RESULTING FROM A DAILY SUBCUTANEOUS PROPHYLAXIS TREATMENT REGIMEN OF DALCINONACOG ALFA (DALCA) IN HEMOPHILIA B
HAEMOPHILIA（2020）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined